Cannabis has been a narcotic drug in Japan since 12 December 2024. Using, possessing, importing and growing it without a licence are all crimes, and using it is now an offence in its own right. CBD products are legal only below fixed residual THC limits, and no cannabis-derived medicine was found approved in Japan as of 16 November 2026.
The short answer
- Recreational use: banned. Using or possessing cannabis carries up to 7 years in prison.
- Medical cannabis: the law now allows approved medicines made from cannabis, but none was found approved as of 16 November 2026.
- CBD and hemp: CBD products must stay under a residual THC limit of 10, 1 or 0.1 ppm, depending on the product form. Licensed farmers may grow hemp. Cannabinol (CBN) products are banned since 1 June 2026.
- Penalties: importing, exporting or growing cannabis carries 1 to 10 years. There is no death penalty and no caning.
- Travel: any narcotic medicine needs permission in advance. Viable cannabis seeds cannot be imported without permission.
The laws that apply
- The 2023 reform law (大麻取締法及び麻薬及び向精神薬取締法の一部を改正する法律, Act No. 84 of 2023). Passed by Japan’s parliament (the Diet) on 6 December 2023 and promulgated on 13 December 2023, it took effect on 12 December 2024 and 1 March 2025.
- Narcotics and Psychotropics Control Act (麻薬及び向精神薬取締法, Act No. 14 of 1953). Since 12 December 2024 cannabis is a narcotic under this act.
- Act on the Regulation of Cannabis Plant Cultivation (大麻草の栽培の規制に関する法律, Act No. 124 of 1948). This is the old Cannabis Control Act, renamed from 12 December 2024. It now covers only growing, grower licences and seeds.
- Cabinet Order No. 238 of 1990, Article 2, which sets the residual THC limits since 12 December 2024.
- Ministry of Health, Labour and Welfare Ordinance No. 24 of 2026, published on 18 March 2026. It made CBN a designated substance (指定薬物) from 1 June 2026.
The Ministry of Health, Labour and Welfare runs the system through its Narcotics Control Department (麻薬取締部).
Medical cannabis
The 2023 reform deleted the old ban on using medicines made from cannabis. Such a medicine now follows the normal rules for narcotic medicines. Only a doctor with a narcotics practitioner licence (麻薬施用者) may give or prescribe it (Article 27).
The best-known candidate is Epidiolex (cannabidiol, a CBD medicine for epilepsy). The industry press reports that cannabidiol received orphan drug designation, a status for rare-disease medicines, in April 2024. It also reports a supply contract between Jazz Pharmaceuticals and Nippon Zoki in April 2026. In May 2026 Jazz said Japanese sales would follow “completion of ongoing clinical trials” and approval.
No cannabis-derived medicine was found approved in Japan as of 16 November 2026. There is no legal route for patients to use cannabis flower.
If you take a cannabis medicine, ask your doctor about an approved alternative before you plan a long stay in Japan.
CBD and hemp
A CBD product is legal only if its residual delta-9-THC is at or below the limit for its form. Above the limit, the product counts as a narcotic.
| Product form (Cabinet Order, Article 2) | Residual THC limit |
|---|---|
| Oils that are liquid at room temperature, and powders | 10 ppm (0.0010%) |
| Water-based solutions, such as drinks | 0.1 ppm (0.000010%) |
| All other products | 1 ppm (0.0001%) |
An oil that is solid at room temperature falls into “all other products”, with the 1 ppm limit.
The Narcotics Control Department offers a voluntary pre-check that a CBD product is not a narcotic. It needs a lab report with the product form, lot number, method and detection limits, and it does not exempt the goods from customs inspection.
Since 1 June 2026, making, importing, selling, possessing or using CBN products is banned outside medical use. The ministry gives the penalty as up to 3 years or a fine of up to ¥3 million. As a business, it is up to 5 years or ¥5 million.
Hemp growing is licensed since 1 March 2025. A Type 1 licence from the prefectural governor covers fibre and seed, using seeds from plants with no more than 0.3% delta-9-THC. The health minister issues Type 2 licences for pharmaceutical raw materials and research licences. Seeds and mature stalks are outside the legal definition of cannabis, but seed imports are still controlled.
Before you ship CBD to Japan, ask the lab to report THC in ppm for the Japanese product form. A result such as “below 0.2%” equals 2,000 ppm and cannot show compliance.
Penalties
A fixed prison term (拘禁刑) in Japan runs from 1 month to 20 years.
| Offence | Law and article | Basic penalty | When done for profit |
|---|---|---|---|
| Import, export or manufacture | Narcotics Act, Article 65 | 1–10 years | 1–20 years, optional fine up to ¥5 million |
| Growing without a licence | Cultivation Act, Article 24 | 1–10 years | 1–20 years, optional fine up to ¥5 million |
| Possession, transfer or receipt | Narcotics Act, Article 66 | up to 7 years | 1–10 years, optional fine up to ¥3 million |
| Use | Narcotics Act, Article 66-2 | up to 7 years | 1–10 years, optional fine up to ¥3 million |
| Importing viable seeds without permission | Cultivation Act, Article 19 | up to 3 years, a fine up to ¥500,000, or both | — |
| Importing treated seeds without a ministry certificate | Cultivation Act, Article 20 | a fine up to ¥200,000 | — |
- Attempts to import, export, possess, use or grow are also punished.
- No weight threshold. No amount presumes trafficking. Acting “for profit” is the aggravating factor, decided by the court.
- No death penalty applies to cannabis, and there is no caning.
- Acts abroad: Japan can prosecute importing, exporting, possessing or growing cannabis even when it happens outside Japan, by anyone.
Treat any cannabis product in Japan, including an untested CBD item, as a possible prison case.
Travelling with cannabis medicines, CBD or seeds
- Narcotic medicines: you may bring one for your own treatment only with permission (Article 13). Apply to a Regional Bureau of Health and Welfare at least two weeks before travel. You must carry it yourself; posting it or giving it to someone else is not allowed. No official guidance specific to foreign cannabis medicines was found.
- CBD products: importing a product above the THC limits is a narcotics crime (Article 65). CBN products are banned.
- Seeds: seeds that can germinate need permission from the Minister of Health, Labour and Welfare (Article 19). Treated seeds need a ministry certificate (Article 20). Customs also asks for a phytosanitary certificate.
In 2025, customs recorded 316 cannabis smuggling cases, down 17%, and seized about 1,531 kg, about 3.5 times the year before. The United States was the origin in 43% of cases, Thailand in 27% and Vietnam in 8% (preliminary figures). For routes and seizures from Thailand, read Taking Cannabis From Thailand to Other Asian Countries: Land and Air Routes, Seizures and Penalties.
Before you fly, apply for any narcotic medicine permit at least two weeks ahead, and leave CBD and seeds out of your luggage unless you hold the papers.
Changes under way
No cannabis bill was found before the Diet as of 16 November 2026. The latest change in force is the CBN ban of 1 June 2026. An approval of Epidiolex is pending and is not law; no official source confirmed a filing or an approval.
Check the ministry’s notices before any CBD import; new substances can be banned by ordinance.
Related reading on Asiannabis
- Cannabis Laws Across Asia and Key Global Markets, 2026: East Asia, South Asia, Israel and Europe (Part 2 of 2)
- Cannabis and Epilepsy: The Approved Cannabidiol Medicine, Its Trials, Doses, Side Effects and Drug Interactions (Part 1 of 2)
- Asia Cannabis Trade Fairs 2026–2027: Japan’s Rules for Samples, the Rest of Asia and Raw-Material Buyer Shows (Part 2 of 2)
- Neighbouring countries: Cannabis Law in South Korea (2026): Case-by-Case Medicines, CBD as Cannabis and Rules Abroad, Cannabis Law in China (2026): No Medical Use, CBD Controls and Criminal Thresholds, Cannabis Law in Taiwan (2026): Category 2 Narcotic, the 10 ppm THC Line and Epidyolex
References
- 麻薬及び向精神薬取締法(昭和二十八年法律第十四号) — e-Gov Laws and Regulations Search, checked 16 November 2026
- 大麻草の栽培の規制に関する法律(昭和二十三年法律第百二十四号) — e-Gov Laws and Regulations Search, checked 16 November 2026
- 麻薬、麻薬原料植物、向精神薬、麻薬向精神薬原料等を指定する政令(平成二年政令第二百三十八号) — e-Gov Laws and Regulations Search, checked 16 November 2026
- 刑法(明治四十年法律第四十五号) — e-Gov Laws and Regulations Search, checked 16 November 2026
- 令和7年3月1日に「大麻取締法及び麻薬及び向精神薬取締法の一部を改正する法律」の一部が施行されます — Ministry of Health, Labour and Welfare, checked 16 November 2026
- 「大麻取締法及び麻薬及び向精神薬取締法の一部を改正する法律」の施行について — Tokyo Metropolitan Government Bureau of Public Health, checked 16 November 2026
- PICK UP! 法令改正情報 — Shin-Nippon Hoki, legal publisher, checked 16 November 2026
- CBDオイル等のCBD関連製品の輸入について — Narcotics Control Department, checked 16 November 2026
- CBD オイル等の CBD 関連製品(※)の輸入を検討されている皆様へ — Narcotics Control Department, 2026
- CBNの指定薬物の指定について — Ministry of Health, Labour and Welfare, checked 16 November 2026
- 危険ドラッグの成分1物質を新たに指定薬物に指定 — Ministry of Health, Labour and Welfare, 18 March 2026
- 【個人向け】 麻薬・覚醒剤原料などを携帯して日本を出入国する方へ — Narcotics Control Department, checked 16 November 2026
- 麻薬、向精神薬及び医薬品である覚醒剤原料の携帯輸出入許可申請について — Kanto-Shinetsu Regional Bureau of Health and Welfare, checked 16 November 2026
- 2005 大麻を原料とする製品の輸入規制 — Japan Customs, checked 16 November 2026
- 令和7年の全国の税関における関税法違反事件の取締り状況(令和8年2月17日)詳細 — Ministry of Finance, 17 February 2026
- 3成分5効能のオーファン指定了承 大麻由来医薬品など、第一部会 — Nikkan Yakugyo, industry press, 2024
- 大麻由来医薬品、国内提供目指し契約 ジャズファーマと日本臓器製薬 — Nikkan Yakugyo, industry press, 2026
- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results — Jazz Pharmaceuticals, filed with the US Securities and Exchange Commission, 5 May 2026
This page summarises the law as checked up to 16 November 2026. It is general information, not legal advice.